Adenovirus infection features and management
Reading File
search_medical_text
adenovirus infection clinical features presentation diagnosis
search_medical_text
adenovirus management treatment antiviral immunocompromised
GradeResponse
GradeResponse
Here is a comprehensive overview of adenovirus infection:
Adenovirus Infection
Overview
Adenoviruses are non-enveloped double-stranded DNA viruses. There are >50 serotypes in humans, and the clinical syndrome largely depends on the serotype and the host's immune status.
Clinical Features
Immunocompetent Hosts
Most infections are mild and self-limiting. Common presentations include:
| Syndrome | Details |
|---|---|
| Upper respiratory tract infection | Pharyngitis, tonsillitis, rhinitis, coryza — often indistinguishable from other viral URTIs |
| Pharyngoconjunctival fever | Pharyngitis + conjunctivitis + fever; serotypes 3, 7 |
| Epidemic keratoconjunctivitis | Keratitis + follicular conjunctivitis; serotypes 8, 19, 37 — highly contagious |
| Pneumonia | Usually in children and military recruits; serotypes 4, 7; can be severe |
| Gastroenteritis | Watery diarrhea, especially in children; serotypes 40, 41 (enteric adenoviruses) |
| Hemorrhagic cystitis | Gross hematuria, dysuria; serotypes 11, 21 |
| Febrile illness in children | Non-specific fever, may trigger wheezing/exacerbation in asthmatic children |
Immunocompromised Hosts
Adenovirus can cause severe or disseminated disease (Guide to Utilization of the Microbiology Laboratory, p. 106):
- Pneumonia (can be fatal)
- Hepatitis (especially post-transplant)
- Hemorrhagic cystitis (HSCT recipients)
- Meningoencephalitis
- Gastroenteritis / colitis
- Disseminated multiorgan infection
High-risk groups: hematopoietic stem cell transplant (HSCT) recipients, solid organ transplant patients, patients with HIV/AIDS, children with combined immunodeficiencies.
Diagnosis
(Guide to Utilization of the Microbiology Laboratory, p. 106)
| Method | Notes |
|---|---|
| NAAT (PCR) | Preferred; high sensitivity and specificity; available on multiplex respiratory panels (FDA-cleared) |
| Quantitative PCR (plasma viral load) | Useful for preemptive therapy in immunocompromised, monitoring treatment response |
| Viral culture | Turnaround 5–7 days; can be expedited with shell vial technology; lower sensitivity |
| Histopathology | "Smudge cells" (basophilic intranuclear inclusions) on biopsy; useful in tissue-invasive disease |
| Antigen detection / DFA | Rapid, but less sensitive than PCR |
| Serology | Limited clinical utility; used mainly in epidemiologic studies |
Key point: Adenovirus is included in FDA-cleared multiplex respiratory panels, making rapid diagnosis feasible in respiratory illness. Plasma quantitative PCR is the cornerstone for monitoring immunocompromised patients.
Management
Immunocompetent Patients
- Supportive care is the mainstay: hydration, antipyretics, symptomatic relief
- No antiviral treatment is routinely indicated
- Conjunctivitis: topical lubricants; avoid topical steroids (can worsen keratoconjunctivitis)
- Hospitalization for severe pneumonia as clinically warranted
Immunocompromised Patients
Antiviral therapy is considered in severe or disseminated disease, though no FDA-approved antiviral exists specifically for adenovirus:
| Agent | Details |
|---|---|
| Cidofovir | Most commonly used; active against adenovirus in vitro and in clinical use; nephrotoxic — must co-administer probenecid and IV hydration; dose reduced/adjusted in renal impairment |
| Brincidofovir (CMX001) | Lipid-conjugated prodrug of cidofovir; oral, better bioavailability, less nephrotoxicity; showed promise in HSCT but FDA approval status for adenovirus remains investigational in most centers |
| Ribavirin | Limited and inconsistent data; occasionally used as adjunct or when cidofovir is not tolerated |
| IVIG / adenovirus-specific immunoglobulin | Adjunctive in severe immunocompromised cases |
| Reduction of immunosuppression | Critical first step in transplant patients if clinically feasible |
Monitoring in Immunocompromised
- Preemptive therapy: regular plasma quantitative PCR surveillance in high-risk HSCT patients; initiate treatment at rising viral loads before overt disease develops
- Response to therapy is monitored by serial plasma viral load measurements
Prevention
- Hand hygiene and contact precautions (fomite transmission is significant)
- Live oral vaccines (serotypes 4 and 7): licensed and used in U.S. military recruits, not available for civilian use
- Droplet and contact precautions in healthcare settings for epidemic keratoconjunctivitis
- Instrument disinfection in ophthalmology clinics (adenovirus is resistant to many common disinfectants; alcohol-based agents have limited efficacy — use sodium hypochlorite or povidone-iodine)
Key Pearls
- Always consider adenovirus in febrile illness post-HSCT — rising plasma PCR warrants preemptive antiviral therapy
- "Smudge cells" on histopathology are classic but not pathognomonic
- Serotype matters: type 7 causes severe pediatric pneumonia; types 40/41 cause enteric disease; types 8/19/37 cause epidemic keratoconjunctivitis
- Adenovirus can persist latently in tonsillar/adenoid tissue and reactivate under immunosuppression
What are the Hb type levels in different thalassemia types
search_medical_text
hemoglobin electrophoresis levels HbA HbA2 HbF thalassemia types alpha beta
search_medical_text
thalassemia classification alpha beta major minor trait hemoglobin pattern
GradeResponse
GradeResponse
search_medical_text
beta thalassemia major intermedia minor HbA2 HbF percentage hemoglobin electrophoresis findings
search_medical_text
alpha thalassemia silent carrier trait HbH Bart hydrops fetalis hemoglobin levels
Here is a comprehensive breakdown of hemoglobin (Hb) type levels across the different thalassemia types:
Hemoglobin Types in Thalassemia
Normal Adult Hemoglobin Reference Values
| Hb Type | Composition | Normal Adult Level |
|---|---|---|
| HbA | α₂β₂ | >95% |
| HbA2 | α₂δ₂ | 1.5–3.5% |
| HbF | α₂γ₂ | <1% |
| HbH | β₄ | Absent |
| Hb Bart's | γ₄ | Absent |
(Harrison's, p. 2906)
Beta (β) Thalassemia
In β-thalassemia, reduced/absent β-globin leads to compensatory increases in HbA2 and HbF (δ and γ chains are upregulated to substitute for β chains).
| Condition | Genotype | HbA | HbA2 | HbF | HbH / Hb Bart's |
|---|---|---|---|---|---|
| Silent carrier | β/β (one mild mutation) | Normal (~97%) | Normal or borderline (~3.5%) | Normal (<1%) | Absent |
| β-Thalassemia Trait (Minor) | β⁺/β or β⁰/β | Reduced (~80–90%) | Raised (>3.5%, typically 4–6%) | Mildly raised (1–5%) | Absent |
| β-Thalassemia Intermedia | β⁺/β⁺ or β⁰/β⁺ | Significantly reduced | Raised (>3.5%) | Markedly raised (10–50%) | Absent |
| β-Thalassemia Major (Cooley's anemia) | β⁰/β⁰ or β⁰/β⁺ (severe) | Absent or trace (<10%) | Raised (>3.5%) | Markedly raised (up to 90–98%) | Absent |
Key rule: In all β-thalassemia states (except silent carrier), HbA2 >3.5% is the hallmark diagnostic finding.
Alpha (α) Thalassemia
In α-thalassemia, reduced/absent α-globin leads to excess β chains (forming HbH = β₄) or excess γ chains in neonates (forming Hb Bart's = γ₄). The severity scales with the number of α-globin genes deleted (normally 4 genes: αα/αα).
| Condition | Genes Deleted | HbA | HbA2 | HbF | HbH (β₄) | Hb Bart's (γ₄) |
|---|---|---|---|---|---|---|
| Silent carrier | 1 gene deleted (-α/αα) | Normal (~98%) | Normal or low-normal (<3.5%) | Normal | Absent | Absent (trace at birth) |
| α-Thalassemia Trait (Minor) | 2 genes deleted (-α/-α or --/αα) | Mildly reduced | Normal or low (<3.5%) | Normal | Absent or trace | 1–2% at birth |
| HbH Disease | 3 genes deleted (--/-α) | Reduced | Low | Low | 5–30% (HbH = β₄) | Present at birth (~20–40%), decreases after |
| Hb Bart's Hydrops Fetalis | 4 genes deleted (--/--) | Absent | Absent | Absent | Trace | >80% Hb Bart's (γ₄); incompatible with life |
Key rule: In α-thalassemia, HbA2 is not elevated (unlike β-thalassemia) — this is a critical diagnostic distinction. Diagnosis relies on molecular/genetic testing or detection of HbH on electrophoresis.
Delta-Beta (δβ) Thalassemia & HPFH
| Condition | HbA | HbA2 | HbF |
|---|---|---|---|
| δβ-Thalassemia trait | Reduced | Normal or low (<3.5%) | Raised (5–20%) |
| Hereditary Persistence of Fetal Hemoglobin (HPFH) — heterozygous | Mildly reduced | Normal | Raised (15–35%) |
| HPFH — homozygous | Absent | Absent | 100% HbF |
δβ-thalassemia and HPFH both elevate HbF but with normal or low HbA2 — distinguishing them from β-thalassemia trait.
Diagnostic Summary Table
| Finding | Suggests |
|---|---|
| HbA2 >3.5% + mild anemia, microcytosis | β-Thalassemia trait |
| HbA2 >3.5% + HbF >50% + severe anemia | β-Thalassemia major/intermedia |
| HbA2 normal/low + microcytosis + no HbA2 rise | α-Thalassemia (genetic testing needed) |
| HbH band on electrophoresis | HbH disease (3-gene α deletion) |
| >80% Hb Bart's at birth + hydrops | 4-gene α deletion |
| HbF 15–35% + low HbA2 | HPFH |
| HbF 5–20% + low HbA2 + microcytosis | δβ-Thalassemia trait |
Key Pearls
- HbA2 elevation (>3.5%) is the single most reliable screening marker for β-thalassemia trait — iron deficiency can falsely lower HbA2, so iron status must be assessed concurrently.
- α-Thalassemia does NOT raise HbA2 — a common exam and clinical pitfall; HPLC/electrophoresis may appear near-normal, requiring DNA analysis.
- Hb Bart's (γ₄) is detectable on neonatal heel-prick screens and is the primary way silent and trait α-thalassemia are now detected early.
- In compound heterozygosity (e.g., HbS/β-thalassemia), sickle cell disease phenotypes emerge alongside thalassemia patterns.
What is the management for foreign body inhalation with complete obstruction
search_medical_text
foreign body airway obstruction complete management emergency adults children
search_medical_text
choking Heimlich maneuver back blows chest thrusts complete airway obstruction
GradeResponse
GradeResponse
Foreign Body Inhalation — Complete Airway Obstruction Management
Complete (severe) airway obstruction is a life-threatening emergency requiring immediate action. The approach is age-dependent.
Recognition of Complete Obstruction
| Feature | Incomplete Obstruction | Complete Obstruction |
|---|---|---|
| Cough | Forceful, effective | Absent or ineffective, silent |
| Speech/cry | Possible | Unable to speak/cry |
| Breathing | Some air movement | None or gasping |
| Skin color | Normal | Cyanosis developing |
| Consciousness | Alert | Deteriorating rapidly |
A patient who cannot cough, speak, or breathe has complete obstruction — act immediately.
Management by Age Group
Adults & Children >1 Year (Conscious)
Step 1 — Encourage coughing
- If any cough is present and effective, encourage continued forceful coughing — do not intervene yet.
Step 2 — 5 Back Blows
- Lean patient forward
- Deliver 5 sharp blows between the shoulder blades with the heel of the hand
- Check after each blow — stop if obstruction relieved
Step 3 — 5 Abdominal Thrusts (Heimlich Maneuver)
(Bailey & Love, p. 283)
- Stand behind patient, one foot forward for stability
- Place one fist (thumb side in) just above the umbilicus and below the xiphisternum
- Grasp fist with other hand
- Give 5 sharp inward and upward thrusts
- Alternate: 5 back blows → 5 abdominal thrusts → repeat cycle
If patient becomes unconscious → start CPR immediately (chest compressions may dislodge the object; look in mouth before each ventilation attempt)
Infants (<1 Year) (Conscious)
(Bailey & Love, p. 283)
Abdominal thrusts are contraindicated in infants due to risk of abdominal organ injury.
Step 1 — 5 Back Blows
- Hold infant face-down, head-down along your forearm
- Support the head
- Deliver 5 firm back blows between shoulder blades with heel of hand
Step 2 — 5 Chest Thrusts (NOT abdominal thrusts)
-
Turn infant face-up, head-down on your thigh
-
Two fingers on lower sternum (one finger-breadth below nipple line)
-
5 sharp downward chest thrusts
-
Alternate cycles and check mouth each time
-
If unconscious → start infant CPR
Pregnant Women & Obese Patients
- Abdominal thrusts are replaced by chest thrusts
- Same position as Heimlich but hands positioned on the lower sternum
In-Hospital / Advanced Management
If basic maneuvers fail or patient is unconscious/arrested:
| Step | Action |
|---|---|
| Direct laryngoscopy | Visualize and attempt removal with Magill forceps if object is in larynx/pharynx |
| Bag-mask ventilation | Attempt oxygenation between removal attempts |
| Rigid bronchoscopy | Definitive method for subglottic/bronchial foreign bodies (Bailey & Love, p. 283, 1005) |
| Surgical airway | Cricothyrotomy or emergency tracheostomy if all else fails and patient cannot be oxygenated |
| CPR | If pulseless — chest compressions may dislodge FB; check oropharynx before each breath |
Post-Removal / Subacute Management
For foreign bodies that have passed beyond the larynx into the bronchial tree (Bailey & Love, p. 1005):
- Right main bronchus (RMB) is the most common site (wider caliber, more vertical)
- Presentations: asymptomatic, unilateral wheeze/obstructive emphysema, or pulmonary suppuration/pneumonia
- Rigid bronchoscopy with a ventilating bronchoscope is the preferred removal technique
- Flexible bronchoscopy used for more distal or peripheral objects
- Chest X-ray (expiratory film): hyperinflated lung, mediastinal shift away from the obstructed side
- If delayed presentation: treat concurrent infection before/during bronchoscopy
Key Pearls
- Do not perform blind finger sweeps — this can push the object deeper
- In infants, always use back blows + chest thrusts (never abdominal thrusts)
- The Heimlich maneuver should not be used in infants or late pregnancy
- Any witnessed choking episode in a child, even if "resolved," warrants bronchoscopic evaluation — objects can lodge silently in the bronchus
- Inspiratory stridor = laryngeal/tracheal obstruction; expiratory wheeze = bronchial obstruction
- RMB involvement is more common due to its anatomy (more vertical, wider)
This is a shared conversation. Sign in to Orris to start your own chat.